Allergan opposes class certification for end payors in Restasis case
MLex Summary: Allergan filed an opposition to end-payor plaintiffs’ motion for class certification in a case accusing the company of delaying a generic version of the drug Restasis. Allergan says several unique...To view the full article, register now.
Already a subscriber? Click here to view full article